Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hello Boys...
I’M BAAAAAAAAAACK!
There has to news coming given the witching hour that occurred last night on the thread! LoL.
WHAT WAS THAT? 28 POSTS IN 1 HOUR?!?!?! THAT WAS AWESOME!
Thanks for the entertainment all!
DCTH IS ON THE LAUNCH PAD.
FALCON HEAVY!!!
Rock on. I jumped in last October and have been segmenting purchases ever since (picked up 150 more this week).
I am here through 2018 and may stay longer, depending on a number of catalysts that I believe are coming this year.
Let’s see what today brings.
GLTY.
About what? He pulled the OS increase to buy himself another 6-12 months before he nukes shareholders with another RS.
He is hoping most of the current shareholders give up, write it off and move on.
Oochie Goochie Cellucci. If ever a DC swamp creature. Disgusting.
Notice the 10K bid. Over the past eight trading days, any time PPS starts to head lower than $2.80, out comes the 10K bid to prop it back up to $3. This has happened no less than ten different times.
With respect to yesterday's presentation, intonation is everything. Jenny sounded passionate in DCTH, confident in its future and most importantly, secure in the present.
You may have been right on the nickel and dime items in the past, but you were wrong on bankruptcy by 31 May 2018. It's now 5 June 2018 and the lights are on--and they will stay on. In the end, you'll also be dead wrong on the only prediction that really matters: PPS.
It's either a partnership, or more likely, offering between $4-$8, IMO.
Until an update comes out from DCTH, we're all just sitting here watching paint dry.
EOM.
Fun Fact: Which of the four DCTH 2018 PR's about presenting at Conferences is different than the other three? (hint: #4).
1. Delcath to Present at 30th Annual Roth Conference. Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcathwill present at the Roth Capital Partners 30th Annual Conference on Tuesday March 13, 2018 at 1:30pm Pacific Time. Dr. Simpson will highlight the recent corporate developments and provide an overview of the Company.
2. Delcath to Present at Oppenheimer 28th Annual Healthcare Conference. Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcathwill present at the Oppenheimer 28th Annual Healthcare Conference on Wednesday March 21, 2018 at 3:55pm Eastern Time. Dr. Simpson will highlight the recent corporate developments and provide an overview of the Company.
3. Delcath to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference. Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held May 8-9, 2018 at Reed Smith, LLP in New York.
4. Delcath Systems to Present at the 8th Annual LD Micro Invitational. Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 12:00pm PST / 3:00pm EST. Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems, will be presenting and meeting with investors.
Oh, and for what it’s worth, per Fintel, SEC Form 13F-HR’s were filed by Gemmer Asset Management (5.11.18) and QCI Asset Management (5.3.18). DCTH Institutional owners up to 5, though it is not clear how much they own.
https://fintel.io/so/us/dcth
Happy Monday.
Bankruptcy talk is a joke; Kudos to H20 for trolling. :)
Put all of this on a single canvas and what picture emerges?
1. Simon Pedder joining BOD;
2. DCTH contract to secure long term increased supply of their delivery drug (focus on Jenny’s ‘economy of scale’ comment);
3. Post-effect amendment to S-1 filing raising total offering amount from $10M to $20M;
4. FDA giving green light a SECOND time in six months to DCTH’s delivery vehicle for the FOCUS trial;
5. ICC trial underway (annual market opportunity between $900M-$1.2B); and
6. The infamous SEC severance package filing giving Jenny, the Pixie and Porn ‘Stache heaps of cash.
Has anyone asked just what the heck oochie goochie celluccci spends all this cash on? Good grief.
The doomsday scenarios posted on this thread 5-7 times a day are quite comical.
Three words: Falcon. Heavy. Soon.
Now, three administrative items:
1. "A big-time partnership could mean $250 million market cap, not an impossibility by any means."
Sam, you complete me.
2. Bankruptcy. H2O (or should I say Baron Von H2O, or maybe Marquis H2O?), we still have plans...get that nonsense out of your head.
3. The ICC Trial is BOOM TIME and would bring in heavy hitters to partner with. Market is $900-$1.2B annually. That's billion with a 'B'.
EOM.
5,000 @ $7.72
FALCON HEAVY ON THE LAUNCHPAD.
https://www.nytimes.com/video/us/100000005723124/watch-the-spacex-falcon-heavy-launch.html
YAWN.
EOM.
Hahahaha. The Canadian holiday. LoL. That still going on?
It's not the "nonevents" that people need to be on the lookout for at this point going forward. They are coming soon, imo.
CHOO CHOO!
With respect to Sam's prior post, he only mentioned the date as indicative that DCTH is not going bankrupt or run out of money by 31 May 2018 as much as some people hope and dream about.
BK simply not happening.
Scooped up a small amount (55) @ $3.12 today. Will continue to accumulate.
Okay, let’s walk through this for the 500th time. Please address the Feb 11th DCTH SEC (S-1) filing wherein Delcath indicates they have cash through May 2018 WITHOUT INCLUSION OF THE $4.5M FROM THE PROCEEDS OF THE OFFERING.
That’s a FACT from the FEB 2018 filing. Go look it up yourself as I have already included a link no less than four previous times.
And Nio, great post: “ignore the results from the previous split as it doesn’t align with my narrative...”
LOL.
IT’S GO TO BE A WONDERFUL WEEK.
I didn’t realize you were the final arbiter of all things content-related on this message board...
DCTH has kept some powder dry. You will see soon enough.
Reverse Split? LoL.
So many people are going to disappointed with how well things are going to turn out.
LONGS BECOME LIONS NEXT WEEK.
LIONS.
LesV,
Good to see you’ve seen the light with this clown show. I hope you were able get out without getting cleaned out.
Best to wait until he does RS, shares dwindle to $.0004 or so then load up. Cellucci can’t help himself.
Shhhhhh. It's all starting to come together...
Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
“We are particularly pleased to be working with a supplier of Tillomed’s caliber and experience as it establishes firm control over our melphalan supply chain in Europe and, over time, will provide economies of scale", noted Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.
ECONOMIES OF SCALE: A proportionate saving in costs gained by an increased level of production.
Read: Additional supply is needed to match the increased demand for the CHEMSAT therapy.
http://delcath.com/investors-news/
Sam-approval in less than 1 year. Let's see what Right to Try brings >:-o
RDR, don't send a PM and then block my response. Don't worry, I am right and so I'll be back on full time soon enough.
Can you all see what's cooking?
"Giddy Up!"
-Kramer, CEO, Kramerika Industries
I downloaded and installed that crap product three years ago. It’s available on Amazon for sale I believe.
That was a hype PR three years ago but like everything else, not a mention or any $$$ revenue ever came of it.
The GUI interface is junk and it looks like a 5 year old designed it. Since BVTK is just Tom dumping shares and generating goof MAPs to cover his butt from litigation, the product will never materialize. There is no product support and the patent gets rejected like George Mcfly.
Tom is the DC swamp that Trump talks about.
Ugh, I have to post here once a day and play nice for another few days or else I can’t free style like Biggie. Once I am out of the pokey, I’ll be on the sidelines waiting for the game to change. It will all be the sweeter, trust me.
I do have to say I’ve enjoyed watching from the sideline as folks pat themselves on the back with such assuredness that DCTH will be out of money in days, all is lost for retail shareholders as not a soul will profit until Rapture.
Matthew 25:13
Good luck fellow longs. I will see you on the other side.
Why hasn’t DCTH “exploited” the tragic cases of ocular melanoma? Is this a serious question?
It’s called human decency.
DCTH offering between $5-$10/share. Expect NASDAQ up list news as well soon.
Mark this post; I’ll return when I am right.
I’m curious, why would they accept an offering lower than the last one, split adjusted?
People talk as if the offering might be at $.006 split adjusted. To me, that’s comedy. Current market cap $3.1M. That’s lunacy.
Mark this post.
Good things are right around the corner, IMO.
FAAAADAAAAAAAH!
BOOV LIKES NEWS OF YESTERDAY SO BOOV BOUGHT MORES. DCTH IS BEST AND ONLY WITH CLINICAL TRIAL SUPPORTING EVIDENCE.
ALL WILL BE GREENS, ESPECIALLY THE DAYS OF FRIDAY!
The GGPO’s update was based on its evaluation of published data on treatment with CHEMOSAT as a loco-regional treatment for melanoma liver metastases. Following this evaluation, and after soliciting additional feedback from the oncology community in Germany, treatment with CHEMOSAT was classified with Evidence Level 1B, indicating the second highest level of evidence. Treatment with CHEMOSAT is the sole therapy classified with this top designation. Other loco-regional therapies previously included in the guidelines have been designated with Evidence Level 4, indicating an absence of clinical trial supporting evidence.
BOOV HOPES SURPRISES HAPPEN SOONS WITH ALL FOUR FINGERS CROSSED...
http://delcath.com/investors-news/
Ive missed you Tom!!!
Enjoy the silence while you can. For anyone with negative sentiment:
* You know something doesn’t seem right. You can’t put your finger on it. The pattern is not the same.
* No massive dilution.
* DCTH issuing PR’s, becoming more transparent.
It’s all coming together, IMO.
Buckle up, it’s going to be one heck of a ride.
Each day brings DCTH closer to FDA APPROVAL.
Each day brings DCTH close to filing the Registration. It won’t disappoint.
TICK TOCK.
TICK TOCK..
TICK TOCK...
BOOM$$$
Mark this post.
LET'S SEE WHO IS LAUGHING BY FRIDAY, IMO.
MOMO IS COMING.
CAN YOU FEEL IT??
TICK TOCK.
BOOM
$$$
You won’t see a dime. Oochie
Goochie Cellucci is a joke.
So much for the fake news that DCTH does have full enrollment for the FOCUS trial.
All 240 accounted for.
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma has completed another review of safety data for treated patients in the trial. The DSMB has again recommended that the study continue without modification.
The FOCUS Trial is evaluating the efficacy, safety and pharmacokinetics of Melphalan/HDS versus best alternative standard of care in 240 patients with metastatic ocular melanoma (OM).
Lol. But wait...when is the HBO special? ROFLMAO.
Hahahaha. I love it.
Happy Friday!!!
FAAAAAADAAAAAAH!!!
1. OS: 896,994 shares - ignore fake news that dilution is occurring.
2. Slowed Q over Q cash burn. NICE!
3. Revenue from European sales for the quarter was $0.7 million.
4. DCTH has 240 patients enrolled in FOCUS - ignore fake news that trials are being canceled all over the U.S.
5. ECONOMIES OF SCALE!!! Need more supply to handle the anticipated increase in demand= secured a commercial supply of melphalan hydrochloride for injection through an agreement with Tillomed Laboratories.
6. ICC Trial (ALIGN) registration begins. This puppy is a monster--the market is between $900,000,000 - $1,200,000,000 ANNUALLY.
7. Don't sleep on Right to Try; oh, and offering is going to surprise, IMO.
8. FOCUS TRIAL GETS ANOTHER GREEN LIGHT TO PROCEED FROM THE FDA!!!
Each day that passes gets us closer to FDA approval.
IT'S ALL COMING TOGETHER!
Play the long game like me and you’ll know exactly where this is headed.
Jenny has spelled it out clearly. If people would take the time to educate themselves and refrain from pearl clutching, they would see what is coming into focus: an 800 lbs gorilla.
And speaking of 800, nice try in guessing my share count. Suffice it to say your guesstimate is, well, paltry.
FAAADAAAAAAAAAAAAAAAAAAAH!!!
BOOV MEETS MANY PEOPLES OF SKILLS IN THE JAILS. I CAN NOW ROB THE BANKS, DO WHITE COLLARS AND TAKE CARS FROM PEOPLES WHO ARE DOING SHOPPINGS IN STORES!
WITH RESPECT TO THE JAILS, BOOV WILL NOT OFFER THE APOLOGIES OR ASKS FOR THE FORGIVENESS.
BOOV WILL ONLY SAY THINGS OF DCTH:
1. THE Q OF 10 IS COMING ANY MOMENT. EUROPE WILL BE FAAADAAAAH!
2. NEWS OF FOCUS TRIAL SITE CLOSURE FAKE NEWS AS PR SAYS 240 PEOPLE ENROLLED.
3. ICC PHASE 3 ROLLING OUT. DCTH SEEMS MARKET OF $900-$1.2 BILLION ANNUALLY. FAAAADAAAAAAH!
4. BOOV IS LONG. BOOV SELLS NONE. BOOV HAS NOT JUMPED OFF BRIDGE AS SUGGESTED WHEN DCTH LAUGHABLE AT $2.50.
5. BOOV IS READY TO CELEBRATE SMECKDAY!
FAAAADAAAAAAH!!!
Ouchie this is going to leave a small mark. If it craters, I’m buying.
Wasn’t expecting this but that’s life.
Bring it.
NASD IS THE PLANS!!!
FADAAAAAAAAAAAHS!!!!
Each new week brings us closer to FDA approval.
BOOM!
BOOVS LOVES HOMES ALONE AND DCTH!!!